Wednesday April 8, 2020

American Biotech Company Works with Chinese Officials to Test Drug Against Coronavirus

Trials to Test Ebola Drug's Potential to Prevent, Treat Coronavirus

0
//
Coronavirus
An American biotech company says it is working with Chinese authorities to determine the efficiency of a drug that can fight coronavirus. Pixabay

By Natalie Liu

An American biotech company says it is working with Chinese authorities to determine whether the antiviral drug remdesivir may provide an effective treatment for victims of the fast-spreading coronavirus known as COVID-19. The Chinese researchers hope to have the answer by May 1.

Officials of Gilead Sciences, which invented remdesivir as a treatment for Ebola and another disease, told VOA the company has initiated two clinical trials among infected patients “to determine the safety and efficacy of remdesivir as a potential treatment for the coronavirus.”

The trials have been warmly welcomed in China, where the nation’s official news agency celebrated the launch with a front page article. Anxious Chinese citizens have noted that the four syllables of remdesivir resemble the phrase as renmin-de-xi-wang, or people’s hope.

Coronavirus
A medical worker holds a thermometer to check a passenger’s temperature at a checkpoint as the country is hit by an outbreak of the coronavirus in Susong County, Anhui province, China. VOA

There are also more scientific reasons to be hopeful, including the case of an American coronavirus patient who experienced a speedy recovery in January, just 24 hours after being given remdesivir. Before the drug was administered, his symptoms had shown signs of worsening.

The first trial began enrolling patients on February 6, said a written statement from Gilead, which says it has provided China with “enough doses of remdesivir to treat up to 500 trial participants.” A Shanghai-based media outlet reported having seen a customs clearance form showing that 2,843 boxes of remdesivir arrived in Beijing on February 4.

The next day, a conference dedicated to the official launch of clinical trials took place at the Jinyintan Hospital in Wuhan, led by Dr. Bin Cao and his colleague Dr. Chen Wang, both top scientists practicing at the China-Japan Friendship Hospital in Beijing. Jinyintan Hospital has been treating some of the most critical COVID-19 cases since the outbreak began.

Gilead confirmed the trials are “being coordinated by the China-Japan Friendship Hospital in Beijing.” A filing registered with the U.S. National Library of Medicine lists the Beijing-based Capital Medical University as the trial’s main sponsor and Cao, a specialist in pulmonary critical care at the China-Japan Friendship Hospital, as the “responsible party.”

Research shows promise

In a scientific paper based on animal studies and published last week, scientists found remdesivir to be effective both for the prevention and treatment of the deadly Middle East Respiratory Syndrome coronavirus (MERS-CoV,) which is known to bear resemblances to COVID-19.

“Remdesivir prevented disease when administered before infection and improved the condition of macaques [monkeys] when given after the animals already were infected,” said scientists at the National Institute of Allergy and Infectious Diseases’ Rocky Mountain Laboratories in Hamilton, Montana.

Coronavirus
A medical worker calls his colleague inside an isolated ward at Jinyintan Hospital in Wuhan, the epicenter of the novel coronavirus outbreak, in Hubei province, China. VOA

Dr. Emmie de Wit, Chief of the Molecular Pathogenesis Unit in the Laboratory of Virology at the Montana facility, told VOA that she and her colleagues conducted their studies and submitted their results for review “well before the world knew of the outbreak in Wuhan.” De Wit said she and her colleagues learned about the coronavirus outbreak on Dec. 31.

Wuhan trials

In the Wuhan study, participants are divided into two groups — those “who have developed more severe clinical manifestations” such as requiring oxygen, and those who do not require oxygen.

“Patients will receive 10 days of intravenously administered remdesivir. The primary endpoint of both studies involves clinical improvement 28 days after treatment,” according to Gilead. Cao reported that 200 mg of remdesivir would be given to a group of patients on day one, followed by 100 mg once-daily “maintenance doses” for nine additional days.

Also Read- Russia Allows Chinese Nationals with Business Visas Despite Entry Ban

Patients in a control group were to be given placebos. To ensure objectivity, the identities of the patients receiving the placebos are masked from the participants, care providers, researchers and outcome assessors.

The researchers say they aim to complete the trials by April 3 and evaluate the results by May 1. (VOA)

Next Story

Indians Spend More Time on OTT Media, Education and Fitness Apps During Coronavirus Lockdown

With the complete lockdown, social media and messaging apps have also seen an instant boom

0
Netflix
OTT platforms like Hotstar, Amazon Prime and Netflix have seen an 82.63 per cent increase in time spent, said the report. Pixabay

With the COVID-19 lockdown keeping most people at home, Indians are now spending more time on over-the-top (OTT) media services and educational and fitness apps than ever, a report said on Wednesday.

After the COVID-19 outbreak in India, video conferencing applications like Zoom, Hangouts, Google Duo, and Houseparty have seen over 71 per cent increase in time spent, with more than 104 per cent increase in active user count, said the report by Gurugram-headquartered tech company Bobble AI.

The findings are based upon the anonymised and aggregated insights collected on Bobble AI platforms post and during the COVID-19 outbreak in India, the company said. While video conferencing desktop and mobile application Houseparty has seen a massive increase of 215.97 per cent in time spent, along with a spike of 8,142.55 per cent in active users, Zoom has seen an increase of 141.69 per cent in time spent, with an 85.43 per cent increase in engagement rate and a 2,542.23 per cent increase in active users, the results showed.

Please Follow NewsGram on Twitter To Get Latest Updates From Around The World!

OTT platforms like Hotstar, Amazon Prime and Netflix have seen an 82.63 per cent increase in time spent, said the report. The Bobble AI data intelligence and analysis revealed that fitness applications like, Lose Weight at Home, Cure.fit, Home Workout has seen a 39.50 per cent increase in time spent with a 14.72 per cent increase in engagement rate, and 104.53 per cent increase in daily active users.

Coronavirus
With the COVID-19 lockdown keeping most people at home, Indians are now spending more time on over-the-top (OTT) media services and educational and fitness apps than ever, a report said on Wednesday. Pixabay

‘Lose Weight at Home’ app has seen a 46.98 per cent increase in time spent, with a 49.33 per cent increase in active users.
Similarly, e-learning platforms like Udemy, Unacademy and Byjus have seen an 82.73 per cent increase in time spent, along with a whopping 122.62 per cent increase in engagement and 25.12 per cent increase in daily active users, said the report.

With the complete lockdown, social media and messaging apps have also seen an instant boom. Applications like Instagram, Facebook, WhatsApp, and Twitter have seen a 46.28 per cent hike in time spent, with a 49.23 per cent increase in engagement and a 29.55 per cent increase in daily active users, said the report.

ALSO READ : Virgin Coconut Oil: The Oldest and the Healthiest Superfood

There is a 57.64 per cent increase in time on WhatsApp, with a 49 per cent increase in engagement, followed by Instagram with a 50.30 per cent increase in engagement rate, it added. (IANS)